Skip to content
value.today

Atox Bio, Inc.

Total raised
$35 M
2 rounds on record
Latest round
$33 M
Dec 2017
First round on record
Dec 2011
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Atox Bio, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2017$33 MNo. 2$10 to $50 million

Atox Bio, Inc.: Raise no. 2, Dec 2017

Investors in this round

15 investors had bought by the notice of Apr 30, 2019: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$33 M of $35 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$386,812
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Anat Shirvan · Executive Officer
  • Dan Teleman · Executive Officer
  • Esther Hayun · Executive Officer
  • Meir Batito · Executive Officer
  • Robert Greif · Executive Officer
  • Wayne Dankner · Executive Officer
  • Casper Breum · Director
  • Dane Ross · Director
  • Daniel Burgess · Director
  • Erez Chimovits · Director
  • Jonathan Tobin · Director
  • Matthew Foy · Director
  • Terry Gould · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • RM GLOBAL PARTNERS LTD. · broker-dealer BEECH HILL SECURITIES, INC. (CRD 24771) · New York, New YorkSold in no state named, and outside the US

Remarks in the notice

  • On fees: “A portion of the amount was provided in shares of Common Stock of the issuer.”
  • On the amounts: “$1,958,780 reserved for sale at a subsequent closing of the offering.”
  • On the use of proceeds: “Excluding amounts paid in the ordinary course of business.”

Signed by Dan Teleman, Ceo. Source: SEC Form D and 1 amendment, newest notice filed Apr 30, 2019. Read the notice at the SEC.

equitySEC
Dec 2011$2 MNo. 1$2 to $10 million

Atox Bio, Inc.: Raise no. 1, Dec 2011

Investors in this round

2 investors had bought by the notice of Jan 24, 2012: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $3 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 505: the former limited-offering exemption (withdrawn in 2017)
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dan Teleman · Executive Officer, Director
  • Arnon Aharon · Director
  • Bob Trachtenberg · Director
  • Newton Becker · Director
  • Raymond Kaempfer · Director
  • Uri Danon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Excluding amounts paid in the ordinary course of business”

Signed by Dan Teleman, Ceo. Source: SEC Form D, newest notice filed Jan 24, 2012. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Atox Bio, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2019).

    SEC Form D · Apr 2019

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Apr 2019

That is all the official record says: Atox Bio, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Atox Bio, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 15 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Atox Bio, Inc.
NameRoleNamed in
Anat ShirvanExecutive officerApr 2019
Dan TelemanExecutive officerApr 2019
Esther HayunExecutive officerApr 2019
Meir BatitoExecutive officerApr 2019
Robert GreifExecutive officerApr 2019
Wayne DanknerExecutive officerApr 2019
Casper BreumDirectorApr 2019
Dane RossDirectorApr 2019
Daniel BurgessDirectorApr 2019
Erez ChimovitsDirectorApr 2019
Jonathan TobinDirectorApr 2019
Matthew FoyDirectorApr 2019
Terry GouldDirectorApr 2019
Arnon AharonDirectorJan 2012
Bob TrachtenbergDirectorJan 2012
Dan TelemanDirectorJan 2012
Newton BeckerDirectorJan 2012
Raymond KaempferDirectorJan 2012
Uri DanonDirectorJan 2012